8-K: U.S. Physical Therapy Posts Record Q3 Visits, Positive 2026 Outlook

U.S. Physical Therapy, Inc. reported strong third-quarter 2025 results with record patient visits and a positive shift in Medicare reimbursement for 2026.

Summary

• Total patient visits increased 18% year-over-year in Q3 2025, reaching 1,524,070 clinic visits and 30,137 home care visits.
• Average visits per clinic per day hit a new Q3 record of 32.2, with September reaching 32.7.
• Gross profit grew 30% year-over-year, with physical therapy (PT) gross profit increasing mid-teens even after accounting for prior year noise.
• Salaries and related costs per visit decreased by $0.40 year-over-year, marking the first decline since Q4 2023.
• Industrial Injury Prevention (IIP) net revenues increased 14.6% organically, with IIP income rising 10.7%.
• Adjusted EBITDA increased 13.2% to $23.9 million for the third quarter.
• The company reaffirmed its full-year 2025 adjusted EBITDA guidance in the range of $93 million to $97 million.
• The final Medicare rule for 2026 is expected to result in a rate increase of 'a little better' than the previously estimated 1.5%, with manual therapy reimbursement shifting from negative to slightly positive.
• Remote Therapeutic Monitoring (RTM) is set for reinitiation in 2026 with reduced visit requirements and a fully integrated app, presenting a significant growth opportunity.
• The company added 84 net PT facilities over the last year and is implementing AI-driven documentation and semi-virtualization of front desk operations, targeting 200 facilities by year-end.

Sentiment

Score: 8

Explanation: The sentiment is highly positive, driven by record Q3 patient visits, strong organic growth in IIP, effective cost management leading to decreased salaries per visit, and a significantly improved outlook for Medicare reimbursement and Remote Therapeutic Monitoring in 2026. The company's strong balance sheet and strategic growth initiatives further bolster confidence, despite minor declines in operating results due to interest dynamics.

Positives

• Record Q3 average visits per clinic per day at 32.2, demonstrating strong operational growth.
• Total patient visits increased 18% year-over-year, driven by acquisitions and a 2.2% increase in mature clinics.
• Gross profit grew 30% year-over-year, indicating strong revenue generation relative to cost of services.
• Salaries and related costs per visit decreased by $0.40, reflecting effective cost management in an inflationary environment.
• IIP segment showed robust organic growth with net revenues up 14.6% and income up 10.7%.
• Adjusted EBITDA increased 13.2% to $23.9 million, showcasing improved profitability.
• The 2026 Medicare final rule is more favorable than anticipated, with an expected rate increase of 'a little better' than 1.5% and a positive reversal for manual therapy reimbursement.
• Remote Therapeutic Monitoring (RTM) is poised for significant growth in 2026 due to reduced visit requirements and a fully integrated system, leading to better patient outcomes.
• High Net Promoter Score (NPS) of over 90, almost mid-90s, across outpatient facilities, indicating strong patient satisfaction.
• Strong balance sheet with $31.1 million in working capital cash and a fixed interest rate on term loan through mid-2027.
• Investments in recruiting have led to reduced time to fill positions and good employee turnover.

Negatives

• Operating results for Q3 2025 were $10.1 million, down slightly from $10.4 million in Q3 2024.
• Lower interest income of $1 million due to cash deployment into acquisitions compared to the prior year.
• Higher interest expense of $400,000 due to increased debt from acquisitions.
• Net rate per patient visit for Q3 2025 was $105.54, down slightly from Q3 2024, partly due to payor mix shifts.
• Workers' compensation visits increased at a lesser rate of 5% compared to commercial (20%) and Medicare (18%) visits, partly cycling against significant prior year increases.
• IIP gross margin decreased by 170 to 200 basis points due to a reallocation of amortization and a mix shift towards auto clients with slightly lower margins.

Risks

• Continued competitive market dynamics in physical therapy, including competition from small practices, hospital-based facilities, and other large providers.
• Impact of balance sheet constraints on private equity-backed companies, potentially affecting acquisition multiples.
• Ongoing inflationary pressures on operating costs, despite recent improvements in salary costs per visit.
• Complexity and potential imprecision in modeling the impact of the 2026 Medicare final rule due to significant changes in geographic index factors and estimation of Medicare Advantage migration.
• Challenges in finding the right personnel to lead new de novo facilities, which can be a limiting factor for expansion.

Future Outlook

The company anticipates a more favorable operating environment in 2026, with the Medicare reimbursement headwind expected to turn into a slight positive, estimated to be 'a little better' than a 1.5% increase. Significant opportunities are foreseen with the reinitiation of Remote Therapeutic Monitoring (RTM) due to reduced regulatory complexities and a fully integrated system. Internal initiatives like AI-driven documentation and semi-virtualization of front desk operations are expected to drive further efficiencies and cost savings. The Industrial Injury Prevention (IIP) business is projected to continue its strong organic growth, supplemented by strategic acquisitions. The company plans to accelerate de novo clinic openings, targeting 30-50 annually, and will provide more detailed guidance for 2026 in February.

Management Comments

• "volume has continued to be strong for us in the quarter. We're up 18%."
• "visits per clinic per day produced a new record for us for Q3 to 32.2, underscoring our ability to continue to grow."
• "our net promoter score is over 90, almost mid-90s, across our entire company for our patients and our out-patient facilities. Just incredible."
• "gross profit grew 30%. I haven't seen those numbers in a long time, even if you just add some of the noise from a year ago, still mid-teens gross profit increase number for PT."
• "manual therapy was slated to go down. We challenged their assumptions, and in this final rule, manual therapy will go up slightly. So, it reversed from the negative to a slight positive."
• "for the first time in a while, we're going to see some blue sky in 2026, particularly in terms of our Medicare reimbursement."
• "This is a team that doesn't give up. We've had a lot of headwinds over the years. It's been challenging. We always find a way."
• "Now that Medicare headwinds are going to be gone, we have some good things in the mix. We still have great capital structure, and we have a very, very strong resolve to take this company forward and do the things that we've said we're going to do."
• "Our PT salaries and related costs per visit actually decreased this quarter. They decreased 40 cents per visit compared to the prior year. That's the first time we've seen a decline in our salaries and related costs since the fourth quarter of 2023."
• "acquisitions will continue to be our primary capital allocation priority, consistent with our long-term growth strategy."
• "we feel good about how things are shaping up for 2026."

Industry Context

The physical therapy industry remains competitive, with U.S. Physical Therapy, Inc. navigating a landscape that includes small independent practices, hospital-based facilities, and larger consolidators. The company notes that some private equity-backed competitors have faced balance sheet constraints, potentially impacting acquisition multiples. A significant shift is occurring in Medicare reimbursement, moving from a multi-year headwind to a more favorable outlook for 2026, which could alleviate pressure across the sector. The broader adoption and improved reimbursement for Remote Therapeutic Monitoring (RTM) reflect a trend towards technology-enabled care delivery and value-based outcomes. The company's ability to manage costs effectively in an inflationary environment, as evidenced by declining salaries per visit, positions it favorably against industry peers facing similar cost pressures.

Comparison to Industry Standards

• The company's Net Promoter Score (NPS) of over 90, almost mid-90s, is exceptionally high and suggests industry-leading patient satisfaction, which is a strong competitive advantage in a service-oriented healthcare sector.
• The 2.2% visit growth in mature clinics, while not as high as overall growth, is a solid performance given the competitive and often fragmented nature of the physical therapy market, where maintaining organic growth can be challenging.
• The ability to decrease salaries and related costs per visit by $0.40 in an inflationary period is a strong indicator of effective operational management and cost control, potentially outperforming peers struggling with rising labor costs.
• The company's strong balance sheet and capital structure, allowing for continued strategic acquisitions and long-term investments, provide a competitive edge over balance sheet-constrained private equity-backed consolidators in the market.

Stakeholder Impact

• Shareholders: Likely to benefit from strong financial performance, positive future outlook, and a commitment to strategic growth and capital allocation, including a share repurchase program (though not yet utilized).
• Patients: Will benefit from continued high-quality care (evidenced by high NPS) and improved outcomes through initiatives like Remote Therapeutic Monitoring.
• Employees: Investments in recruiting and improved retention suggest a positive environment, while new systems (ERP, AI documentation) aim to enhance efficiency.
• Creditors: The company's healthy balance sheet, managed debt, and fixed interest rates provide stability and confidence.
• Customers (IIP): Will continue to receive expanded services and programs from a growing and strengthening Industrial Injury Prevention business.

Next Steps

• Continue rolling out AI-driven documentation and semi-virtualization of front desk operations, targeting 200 facilities by year-end.
• Reinitiate and expand Remote Therapeutic Monitoring (RTM) opportunities starting in 2026.
• Add several new workers' compensation network relationships before the end of 2025.
• Continue to pursue strategic acquisitions, particularly in the Industrial Injury Prevention (IIP) segment.
• Accelerate de novo clinic openings, aiming for a range of 30-50 annually.
• Provide a more detailed update on the Medicare impact and other strategic initiatives, along with 2026 guidance, during the year-end earnings call in February.

Key Dates

Recommendation

U.S. Physical Therapy, Inc. delivered a strong third quarter with record patient volumes and effective cost management, leading to a significant increase in adjusted EBITDA. The most compelling aspect is the positive shift in the 2026 Medicare reimbursement outlook, which removes a long-standing headwind and introduces 'blue sky' for the first time in years. Coupled with the reinitiation of Remote Therapeutic Monitoring and ongoing efficiency initiatives (AI documentation, virtual front desk), the company is well-positioned for accelerated organic growth and margin expansion. The robust organic growth in the Industrial Injury Prevention segment and a healthy acquisition pipeline further strengthen the long-term growth trajectory. The strong balance sheet provides ample flexibility for continued strategic investments. While operating results were slightly down due to interest dynamics, the underlying operational performance and future prospects warrant a 'buy' recommendation for investors seeking exposure to a growing and well-managed healthcare services provider.

Keywords

Physical Therapy, Outpatient Clinics, Industrial Injury Prevention, SEC Filing, Earnings Call, Q3 2025 Results, Medicare Reimbursement, Remote Therapeutic Monitoring, Adjusted EBITDA, Patient Visits, Cost Management, Acquisitions, De Novos, Healthcare Services, USPH